Barclays PLC Acquires 61,486 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Barclays PLC grew its position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 325.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 80,407 shares of the company's stock after purchasing an additional 61,486 shares during the period. Barclays PLC owned approximately 0.29% of GeneDx worth $6,180,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Franklin Resources Inc. bought a new position in shares of GeneDx in the third quarter valued at approximately $301,000. Prudential Financial Inc. bought a new position in shares of GeneDx in the fourth quarter valued at approximately $7,938,000. JPMorgan Chase & Co. boosted its holdings in shares of GeneDx by 617.3% in the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company's stock valued at $2,214,000 after acquiring an additional 44,889 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of GeneDx in the third quarter valued at approximately $604,000. Finally, Geode Capital Management LLC lifted its stake in GeneDx by 8.7% during the third quarter. Geode Capital Management LLC now owns 377,631 shares of the company's stock valued at $16,030,000 after purchasing an additional 30,379 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

Insider Buying and Selling

In other GeneDx news, CFO Kevin Feeley sold 922 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the completion of the transaction, the chief financial officer now owns 5,446 shares of the company's stock, valued at $515,845.12. This represents a 14.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Katherine Stueland sold 1,078 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $89.44, for a total value of $96,416.32. Following the completion of the transaction, the chief executive officer now directly owns 6,674 shares of the company's stock, valued at approximately $596,922.56. This trade represents a 13.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 138,780 shares of company stock valued at $12,907,437. Insiders own 27.30% of the company's stock.

GeneDx Stock Up 1.3 %

GeneDx stock traded up $1.48 during trading hours on Monday, hitting $112.49. The company had a trading volume of 1,376,865 shares, compared to its average volume of 702,047. The firm's fifty day moving average is $95.80 and its 200-day moving average is $82.37. GeneDx Holdings Corp. has a fifty-two week low of $10.70 and a fifty-two week high of $116.01. The firm has a market capitalization of $3.16 billion, a P/E ratio of -57.39 and a beta of 1.93. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. On average, research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Analysts Set New Price Targets

WGS has been the subject of several recent research reports. The Goldman Sachs Group increased their target price on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen increased their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $72.33.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.